Novo Nordisk’s OASIS 4 Study Validates Daily Oral Pill for Chronic Weight Management

A new year brings a new therapeutic milestone for weight management: Following its recent U.S. Food and Drug Administration approval, the 25 mg oral semaglutide tablet (brand name: Wegovy), a once-daily pill became available in the United States in early January 2026 for chronic weight management and for reducing the risk of major adverse cardiovascular events in adults living with obesity or overweight and established cardiovascular disease.

According to results from the OASIS (Oral Semaglutide Treatment Effect in People with Obesity) 4 clinical trial recently published in the New England Journal of Medicine , a daily 25 mg dose leads to significant weight reduction and improved physical function. The study positions this mid-dose oral option as a potent alternative for patients who prefer the convenience of a pill over standard weekly injections or higher-dose oral formulations.

“The reasons patients may prefer oral administration over the subcutaneous route are most often needle aversion and local skin reactions,” the authors write.